Cargando…

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis

INTRODUCTION: Radiotherapy may augment systemic antitumor responses to immunotherapy. We did a retrospective study to infer whether radiotherapy improves outcomes to immunotherapy in patients with stage III and IV non-small-cell lung cancer (NSCLC). METHODS: This retrospective study conducted at Enz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shuling, Chen, Kuifei, Yang, Meiwen, Hlaing, Swe Swe, Chen, Meng, Gu, Pinjun, Meng, Yinnan, Yang, Haihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521490/ https://www.ncbi.nlm.nih.gov/pubmed/36189277 http://dx.doi.org/10.3389/fimmu.2022.991431

Ejemplares similares

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer
por: Meng, Yinnan, et al.
Publicado: (2021)

The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study
por: Chen, Meng, et al.
Publicado: (2022)

Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling
por: Wang, Wei, et al.
Publicado: (2021)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Failure patterns of locoregional recurrence after reducing target volumes in patients with nasopharyngeal carcinoma receiving adaptive replanning during intensity-modulated radiotherapy: a single-center experience in China
por: Zhou, Xiate, et al.
Publicado: (2023)

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
por: Shen, Jie, et al.
Publicado: (2023)

Predicting the Efficacy of SBRT for Lung Cancer with (18)F-FDG PET/CT Radiogenomics
por: Chen, Kuifei, et al.
Publicado: (2023)

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors
por: Ji, Xiaoqin, et al.
Publicado: (2023)

Wandering Cancer Cells: Metastatic Renal Cell Carcinoma Without Evidence of a Primary Tumor
por: Hlaing, Swe Swe, et al.
Publicado: (2022)

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
por: Zhou, Suna, et al.
Publicado: (2023)

The Tale of a Rubbery White Clot: Poorly Differentiated Spindle Cell Sarcoma Presenting As Superior Vena Cava Syndrome
por: Hlaing, Swe Swe, et al.
Publicado: (2022)

Impending Doom: A Rare Case of Metastatic Myoepithelial Carcinoma
por: Ugwuegbulem, Emeka, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
por: Hong, Guo, et al.
Publicado: (2023)

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
por: Wen, Liang, et al.
Publicado: (2020)

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
por: Ji, Hongxiang, et al.
Publicado: (2022)

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
por: Wu, Yijun, et al.
Publicado: (2022)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

DIEULAFOY LESION CAUSING LOWER GI BLEEDING: A CASE OF COVID-19 CRITICAL ILLNESS PROMPTING UNUSUAL PRESENTATION OF A MORE RARE CONDITION
por: TAHIR, MUHAMMAD MOIZ, et al.
Publicado: (2022)

Erratum: Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer
Publicado: (2022)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
por: Wang, Min, et al.
Publicado: (2022)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma
por: Li, Chao, et al.
Publicado: (2022)

Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching
por: Tang, Cuiping, et al.
Publicado: (2023)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
por: Onn, Amir, et al.
Publicado: (2021)

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
por: Li, Gang, et al.
Publicado: (2022)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
por: Zeng, Xianghua, et al.
Publicado: (2023)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_un7d7a59adsh2vtb9bi5ghrrvv